Sheba’s Innovalve Bio Medical LTD Acquired by Edwards Lifesciences Corporation
Innovalve, founded in 2017 at ARC Innovation, Sheba’s innovation arm, has developed an artificial mitral valve designed to be replaced using a minimally invasive catheter, addressing the needs of heart disease patients. The company has secured FDA approval for clinical studies and has successfully performed over 40 surgeries to date.
The creation of Innovalve was driven by the pioneering efforts of Prof. Ehud Raanani, Director of Sheba’s Cardiovascular and Thoracic Center, and Dr. Boris Orlev, Head of Sheba’s Mitral Valve Surgery Unit. Under the leadership of CEO Eyal Bar-Or, Innovalve has benefited from close collaboration with Sheba’s clinicians and developers.
This acquisition marks a significant step in the integration of cutting-edge technologies into Edwards’ transcatheter mitral and tricuspid therapies (TMTT) product group.
Prof. Yitshak Kreiss, Director General of Sheba Medical Center, commented on the acquisition:
“The health system is an engine of economic growth for the Israeli economy. Innovalve’s exit joins other Sheba companies acquired in recent months by international biomed giants, which have repeatedly expressed confidence in innovation coming out of Sheba. These achievements are made possible thanks to ARC – Sheba’s unique innovation platform, which encourages the development of groundbreaking technologies through the combination of technological entrepreneurship and extensive clinical knowledge and experience at the patient’s bedside. Soon we will see more and more deals of this kind, the fruits of which strengthen and develop the public health system. This is a real revolution that transforms the health system, which for years had to budget for the state, into a factor that generates significant revenues for the Israeli economy.”


